243641-37-4

Basic information

• Product Name: 7-METHYL-3,4-DIHYDRO-2H-[1,8]NAPHTHYRIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 7-METHYL-3,4-DIHYDRO-2H-[1,8]NAPHTHYRIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-7-methyl-1,2,3,4-tetrahydro-1,8-naphthyridine;1-BOC-7-METHYL-3,4-DIHYDRO-2H-[1,8]NAPHTHYRIDINE;1,8-Naphthyridine-1(2H)-carboxylic acid, 3,4-dihydro-7-methyl-, 1,1-dimethylethyl ester;tert-butyl7-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate;tert-butyl 7-methyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate
• CAS NO: 243641-37-4
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.32
• Mol File: 243641-37-4.mol

Chemical Properties

• Melting Point: 99.8-99.9°C
• Boiling Point: 364.7°Cat760mmHg
• Flash Point: 174.3°C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: 7-METHYL-3,4-DIHYDRO-2H-[1,8]NAPHTHYRIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHYL-3,4-DIHYDRO-2H-[1,8]NAPHTHYRIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(243641-37-4)
• EPA Substance Registry System: 7-METHYL-3,4-DIHYDRO-2H-[1,8]NAPHTHYRIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(243641-37-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 243641-37-4(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not specify the uses of 7-Methyl-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester, it is not possible to list its applications based on the given information. Further research or data would be required to determine its potential uses in various industries or applications.

InChI:InChI=1/C14H20N2O2/c1-10-7-8-11-6-5-9-16(12(11)15-10)13(17)18-14(2,3)4/h7-8H,5-6,9H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 274676-47-0 7-methyl-1,2,3,4-tetrahydro-[1,8]naphthyridine 
• 504-29-0 2-aminopyridine 
• 7521-41-7 2-Aminonicotinaldehyde 
• 76293-30-6 N-tert-butyl-2-aminopyridine 
• 1569-16-0 2-methyl-[1,8]naphthyridine 
• 855313-30-3 2-tert-butylamino-pyridine-3-carbaldehyde 
• 1824-81-3 2-Amino-6-methylpyridine 
• 55469-90-4 7-methyl-2,3-dihydro-1,8-naphthyridin-4-(1H)one 
• 55469-89-1 N-(6-methyl-[2]pyridyl)-β-alanine 
• 1292955-81-7 C₉H₁₂N₂O 
• 1292237-99-0 ethyl 3-[(6-methylpyridine-2-yl)amino]propionate 

Downstream Products

• 445492-19-3 (8-N-Boc-5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)acetic acid 
• 445490-79-9 7-[2-(3-methyl-4-nitro-phenoxy)-ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 855313-35-8 7-[1,1-difluoro-2-(3-methyl-4-nitro-phenoxy)-ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445489-88-3 3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid 
• 445490-83-5 3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-32-7 3-(3-chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-20-3 3-(2-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-23-6 3-(3-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-26-9 3-(4-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-06-5 3-biphenyl-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445490-82-4 7-{2-[1-(2-ethoxycarbonyl-1-phenyl-ethyl)-1H-indol-5-yloxy]-ethyl}-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445491-31-6 7-(2-{1-[1-(3-Chloro-phenyl)-2-ethoxycarbonyl-ethyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Pyrrolidine integrin regulator and application thereof

Disclosed are a compound as represented by formula I, and a racemate, a stereoisomer, a tautomer, an isotopic marker, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, and a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method therefor, and the medical use thereof. The structure of formula I is as follows:

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

Facile preparation of thiophene C2-ethers using the Mitsunobu reaction

The preparation of thiophene ethers generally requires forcing conditions thus limiting the choice of alkyl substituent. Herein, we report the first successful generally applicable conditions for the selective O-alkylation of 2(5H)-thiophenone.

Non-peptidic αvβ3 antagonists containing indol-1-yl propionic acids

We describe the synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ 3. Indol-1-yl propionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified.

NOVEL PROCESSES FOR THE SYNTHESIS OF CYCLOPROPYL COMPOUNDS

This invention relates to processes for the preparation of cyclopropyl compounds of Formula: (I) wherein: x is an integer selected from the group consisting of 0, 1 and 2; R and R are independently selected from the group consisting of H, C1-C6 alkyl, and halo; and R, R, R, R and R are independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, and halo.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

VITRONECTIN RECEPTOR ANTAGONISTS

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein R is Het- or Ar; R is formula (a) or formula (b); or a pharmaceutically acceptable salt thereof.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.